TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29758071

Group type: EXPERIMENTAL
Intervention: Participatory learning and action (PLA) intervention
Number of subjects: 4030

Group type: EXPERIMENTAL
Intervention: Subsequent exposure to PLA groups
Number of subjects: 4030
Study: 28830555

Group type: EXPERIMENTAL
Intervention: Work-focused cognitive behavioral therapy (6 sessions) and a small workplace intervention
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group A (clinical examination)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group B (no offers at the department)
Number of subjects: 163
Study: 25297643

Group type: EXPERIMENTAL
Intervention: Prophylactic vitamin K (single dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No prophylactic vitamin K (control group)
Number of subjects: 120
Study: 23244776

Group type: EXPERIMENTAL
Intervention: Low habit strength group
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Medium habit strength group
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: High habit strength group
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Strong PA habit group
Number of subjects: 1836
Study: 21372622

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) added to Treatment as Usual (TAU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 50
Study: 18081756

Group type: EXPERIMENTAL
Intervention: Phonology with Reading (P + R) programme
Number of subjects: 152

Group type: COMPARATOR
Intervention: Oral Language (OL) programme
Number of subjects: 152
Study: 17068786

Group type: EXPERIMENTAL
Intervention: Active rTMS (1Hz, 1,200 pulses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study: 12496571

Group type: EXPERIMENTAL
Intervention: Closed suction drainage in the right breast
Number of subjects: 49

Group type: COMPARATOR
Intervention: No closed suction drainage in the left breast
Number of subjects: 49
Study: 10833090

Group type: EXPERIMENTAL
Intervention: Pan+Amo+Cla (40 mg b.i.d. Pantoprazole, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Number of subjects: 150

Group type: COMPARATOR
Intervention: RBC+Amo+Cla (400 mg b.i.d. Ranitidine bismuth citrate, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Number of subjects: 150
Study: 10183331

Group type: EXPERIMENTAL
Intervention: Certified mail
Number of subjects: 409

Group type: COMPARATOR
Intervention: First-class mail
Number of subjects: 409
Study: 7979074

Group type: EXPERIMENTAL
Intervention: Epidural infusion of bupivacaine 75 mg, clonidine 150 micrograms, and diamorphine 5 mg in 60 ml normal saline at 1-4 ml/h for 24-48 hours preoperatively and maintained for at least 3 days postoperatively
Number of subjects: 24

Group type: COMPARATOR
Intervention: On-demand opioid analgesia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Epidural infusion of bupivacaine, clonidine, and diamorphine
Number of subjects: 24
Study: 2690971

Group type: EXPERIMENTAL
Intervention: EGFR-positive tumors
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EGFR+/ER- patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EGFR levels
Number of subjects: 68
Study: 776537

Group type: EXPERIMENTAL
Intervention: 0.5 mg flupenthixol 2 to 4-times daily for 2 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Identical placebo tablets 2 to 4-times daily for 2 weeks
Number of subjects: 43
Study: 31311366

Group type: EXPERIMENTAL
Intervention: AlloDerm myringoplasty (Group 1)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Perichondrium myringoplasty (Group 2)
Number of subjects: 61
Study: 29083206

Group type: EXPERIMENTAL
Intervention: SSSR-F (Strengthening Same-Sex Relationships Program, Female version)
Number of subjects: 37
Study: 25040180

Group type: EXPERIMENTAL
Intervention: CLNP/BPO 3·0% twice daily
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: CLNP/BPO 3·0% once daily
Number of subjects: 800
Study: 23224626

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/day) and vitamin D (60,000 IU/3 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/day), vitamin D (60,000 IU/3 months), and zinc (as per Indian Recommended Allowance)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Growth hormone therapy
Number of subjects: 31
Study: 21613427

Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 108

Group type: COMPARATOR
Intervention: BIV pacing
Number of subjects: 108
Study: 19249659

Group type: EXPERIMENTAL
Intervention: Zhi Byed 11 (ZB11)
Number of subjects: 967

Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 967
Study: 16896957

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 36
Study: 15333468

Group type: EXPERIMENTAL
Intervention: ACCalpha haplotype associated with breast cancer risk
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Common ACCalpha alleles
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Three other haplotypes
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Mutations in the ACCalpha gene
Number of subjects: 453
Study: 11295650

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg twice daily for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7498360

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEpo) treatment; specific dosage and duration not mentioned.
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (control group); 12 patients without PB CFU-E.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Presence of PB CFU-E; no specific treatment mentioned.
Number of subjects: 18
Study: 2023754

Group type: EXPERIMENTAL
Intervention: Pulse therapy (prednisolone acetate 1% drops hourly and a single intravenous pulse of 500 mg methylprednisolone)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral therapy (same topical therapy plus oral prednisone 60 to 80 mg daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pulse therapy (for patients treated early, less than or equal to 8 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral therapy (for patients treated early, less than or equal to 8 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pulse therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral therapy
Number of subjects: 48
Study: 7032681

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum combined with radiation therapy (4 mg/m2 into tumor-bearing lymph nodes and 2, 2, 4, 4, and 4 mg/m2 intravenously at specified days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 57
Study: 30264631

Group type: EXPERIMENTAL
Intervention: Splint group (n=39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 80
Study: 28739062

Group type: EXPERIMENTAL
Intervention: Cervical collar intervention after operation, kept on until mobilization
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group with no head and neck immobilization
Number of subjects: 120
Study: 26397834

Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Veress Needle Insertion (VNI)
Number of subjects: 81
Study: 23577903

Group type: EXPERIMENTAL
Intervention: In vivo (IV) approach
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Distance learning (DL) approach
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control condition (C)
Number of subjects: 143
Study: 21289525

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 5 mg
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 10 mg
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 18777173

Group type: EXPERIMENTAL
Intervention: Topical miconazole oral gel (85 mg x 3, 3 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral voriconazole (400 mg x 2, 1st day, 200 mg x 2, 2nd day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No pretreatment (control)
Number of subjects: 12
Study: 17725472

Group type: EXPERIMENTAL
Intervention: Laser therapy plus exercise
Number of subjects: 61
Study: 14747427

Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg, 10 mg, 15 mg, 20 mg once daily (Study 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aripiprazole titrated from 10 to 30 mg/day (Study 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (Study 1 and Study 2)
Number of subjects: 48
Study: 11393383

Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg and Isradipine 2.5 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy (Spirapril and Isradipine)
Number of subjects: 60
Study: 9605896

Group type: COMPARATOR
Intervention: Abstinence intervention
Number of subjects: 659

Group type: COMPARATOR
Intervention: Safer-sex intervention
Number of subjects: 659

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 659
Study: 9950664

Group type: EXPERIMENTAL
Intervention: Slow pathway ablation in group 1 (continuous AVN conduction curves)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Slow pathway ablation in group 2 (discontinuous AVN conduction curves)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: A1A2A3 stimulation
Number of subjects: 136
Study: 2565917

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 332217

Group type: EXPERIMENTAL
Intervention: 20 mg xipamid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg xipamid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31811128

Group type: EXPERIMENTAL
Intervention: Supervised high-dose primaquine
Number of subjects: 1299

Group type: COMPARATOR
Intervention: No primaquine treatment
Number of subjects: 1299
Study: 28941934

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (140 ml of concentrated beetroot juice)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted beetroot juice)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 13
Study: 26467594

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control
Number of subjects: 171
Study: 23578495

Group type: EXPERIMENTAL
Intervention: Method of inter‐active problem solving targeted at the functioning of the teams
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Method for developing professional practice centred on individual
Number of subjects: 54
Study: 22024266

Group type: EXPERIMENTAL
Intervention: AlphaScope
Number of subjects: 150

Group type: COMPARATOR
Intervention: LBH
Number of subjects: 150
Study: 19491535

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosiglitazone plus glimepiride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide or glimepiride
Number of subjects: 0
Study: 16479244

Group type: EXPERIMENTAL
Intervention: Verapamil (group 1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (group 2)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Verapamil administration
Number of subjects: 101
Study: 15553660

Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg b.i.d. for 8 months)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 11761117

Group type: EXPERIMENTAL
Intervention: Low dose group (168‐255 microg of each phthalate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High dose group (336 to 510 microg of each phthalate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no dose)
Number of subjects: 24
Study: 9247840

Group type: EXPERIMENTAL
Intervention: Cimetidine 1,000 mg daily over 20 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine treatment with metamizol doses of 750 mg and 1,500 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 12
Study: 7506164

Group type: EXPERIMENTAL
Intervention: nimesulide (200mg twice daily)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: ketoprofen (100mg twice daily)
Number of subjects: 76
Study: 2428719

Group type: EXPERIMENTAL
Intervention: Depot secretin therapy (800 CU by subcutaneous injection twice daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29935790

Group type: EXPERIMENTAL
Intervention: Calvarial bone harvesting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anterior iliac crest bone harvesting
Number of subjects: 20
Study: 26179237

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg alone under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg after a high-fat, high-calorie meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dacomitinib 45 mg coadministered with rabeprazole 40 mg under fasting conditions
Number of subjects: 24
Study: 24996856

Group type: EXPERIMENTAL
Intervention: EVAA appliance
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Activator appliance
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 22718380

Group type: EXPERIMENTAL
Intervention: Haemodynamic evaluation by ICG (HD)
Number of subjects: 82
Study: 19277623

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 2 weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 17848492

Group type: EXPERIMENTAL
Intervention: Novel clinical trial design (sequential parallel design)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical trial design (conventional two arm)
Number of subjects: 0
Study: 15470214

Group type: EXPERIMENTAL
Intervention: Docetaxel and estramustine
Number of subjects: 770

Group type: COMPARATOR
Intervention: Mitoxantrone and prednisone
Number of subjects: 770
Study: 11406729

Group type: EXPERIMENTAL
Intervention: Warfarin 1 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warfarin 2 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warfarin 3 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9720470

Group type: EXPERIMENTAL
Intervention: Cefaclor (40 mg/kg/day for 10 days)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cefuroxime axetil (30 mg/kg/day for 10 days)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 205
Study: 8113850

Group type: EXPERIMENTAL
Intervention: Western surgical resection with limited lymphadenectomy (R1)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Japanese surgical resection with extended lymphadenectomy (R2)
Number of subjects: 237
Study: 3053887

Group type: EXPERIMENTAL
Intervention: Lactitol (10 g/6 h)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lactulose (15 ml/6 h, 66% w/v, containing 10 g of lactulose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 25
Study: 7142087

Group type: EXPERIMENTAL
Intervention: Single dose of 500 mg cefadroxil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of 1 g cefadroxil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three repeated doses of 500 mg cefadroxil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two repeated doses of 1 g cefadroxil
Number of subjects: 0
Study: 31262022

Group type: EXPERIMENTAL
Intervention: Dietary interventions; specific interventions not detailed in the abstract.
Number of subjects: 0
Study: 29043493

Group type: EXPERIMENTAL
Intervention: 6 week physical activity intervention (four sessions delivered over a 6-week period by a trained physiotherapist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (physical activity information leaflet)
Number of subjects: 0
Study: 25542912

Group type: EXPERIMENTAL
Intervention: Intention to return to smoking
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Demographic and smoking factors
Number of subjects: 382
Study: 24799467

Group type: EXPERIMENTAL
Intervention: MyVax (Id coupled to KLH plus GM-CSF), n=195
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control immunotherapy (KLH plus GM-CSF)
Number of subjects: 287
Study: 22691628

Group type: EXPERIMENTAL
Intervention: Masitinib (3 to 6 mg/kg/day for at least 12 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Masitinib and Placebo
Number of subjects: 35
Study: 19284395

Group type: EXPERIMENTAL
Intervention: Kinesiotherapy and functional electrical stimulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Kinesiotherapy only
Number of subjects: 80
Study: 17545861

Group type: COMPARATOR
Intervention: Sublingual house dust-mite-specific immunotherapy for 2 years followed by 1 year of placebo (Group A)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Sublingual house dust-mite-specific immunotherapy for 3 years (Group B)
Number of subjects: 137
Study: 14991953

Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg + amoxicillin 1 000 mg + clarithromycin 250 mg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: OFC (omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 20 mg + metronidazole 200 mg + clarithromycin 250 mg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: OFA (omeprazole 20 mg + furazolidone 100 mg + amoxicillin 1 000 mg)
Number of subjects: 132
Study: 12217090

Group type: EXPERIMENTAL
Intervention: Six months of structured exercise program
Number of subjects: 174
Study: 9642706

Group type: EXPERIMENTAL
Intervention: Single-limb standing test for proprioception in ACL-deficient knee
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 32
Study: 8818160

Group type: EXPERIMENTAL
Intervention: Memorizing positions of words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memorizing words
Number of subjects: 0
Study: 2689913

Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 802922

Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinized succus
Number of subjects: 0
Study: 29799268

Group type: EXPERIMENTAL
Intervention: Arthroscopic abrasion arthroplasty
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 26
Study: 28591155

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg orally twice daily for five days)
Number of subjects: 20
Study: 25957214

Group type: EXPERIMENTAL
Intervention: Prophylaxis antibiotics
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24166282

Group type: EXPERIMENTAL
Intervention: Weekly ixabepilone 16 mg/m2 as a 1-h IV infusion weekly on days 1, 8, and 15 of a 28-day cycle (1 week off therapy); n=85
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Every-3-week ixabepilone 40 mg/m2 as a 3-h IV infusion on day 1 of a 21-day cycle; n=91
Number of subjects: 176
Study: 21749265

Group type: EXPERIMENTAL
Intervention: Tilting Whole Body Vibration therapy (WBV) for 12 weeks (12.5-Hz frequency; 3-mm amplitude)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 19453534

Group type: COMPARATOR
Intervention: Standard Wedged Tangents (SWT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tangential Beam IMRT (T‐IMRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non‐Coplanar Multi‐Field IMRT (NCP‐IMRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electronic Compensators IMRT (E‐IMRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coplanar Multi‐Field IMRT (CP‐IMRT)
Number of subjects: 20
Study: 17544776

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 165

Group type: COMPARATOR
Intervention: Combination of PDT with verteporfin and intravitreal bevacizumab
Number of subjects: 165
Study: 15215482

Group type: EXPERIMENTAL
Intervention: Topical alpha-lactalbumin-oleic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical alpha-lactalbumin-oleic acid (second phase)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical alpha-lactalbumin-oleic acid (long-term follow-up)
Number of subjects: 40
Study: 11838750

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 175

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 175
Study: 9734615

Group type: EXPERIMENTAL
Intervention: Intraperitoneal calcitriol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oral calcitriol
Number of subjects: 46
Study: 8090391

Group type: EXPERIMENTAL
Intervention: Prophylactic saline amnioinfusion (600‐mL bolus followed by 3 mL/minute)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard obstetric care (control)
Number of subjects: 116
Study: 3335145

Group type: EXPERIMENTAL
Intervention: Smoking six cigarettes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 52
Study: 31564843

Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation) at Neiguan [PC6] and Ximen [PC4] for 30 minutes before anesthesia induction until the end of surgery
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (electrode plate at the same acupuncture points without electrical stimulation)
Number of subjects: 122